• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Replimune Group, Inc. - Common Stock (NQ:REPL)

    13.40 +0.16 (+1.21%)
    Delayed Quote Updated: 3:50 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,916,253
    Open 13.26
    Bid (Size) 13.38 (300)
    Ask (Size) 13.40 (200)
    Prev. Close 13.24
    Today's Range 13.05 - 13.58
    52wk Range 1.500 - 16.33
    Shares Outstanding 46,772,263
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
    ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live 
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Performance

    YTD
    +50.6%
    +50.6%
    1 Month
    -12.4%
    -12.4%
    3 Month
    +19.4%
    +19.4%
    6 Month
    +76.1%
    +76.1%
    1 Year
    +219.8%
    +219.8%

    More News

    Read More
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
    Via Newsfile
    Topics Lawsuit
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    Replimune to Present at the Cantor Global Healthcare Conference 2026
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.
    From Robbins LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Replimune Group, Inc. - Common Stock publicly traded?
    Yes, Replimune Group, Inc. - Common Stock is publicly traded.
    What exchange does Replimune Group, Inc. - Common Stock trade on?
    Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Replimune Group, Inc. - Common Stock?
    The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market
    What is the current price of Replimune Group, Inc. - Common Stock?
    The current price of Replimune Group, Inc. - Common Stock is 13.40
    When was Replimune Group, Inc. - Common Stock last traded?
    The last trade of Replimune Group, Inc. - Common Stock was at 10/01/26 03:50 PM ET
    What is the market capitalization of Replimune Group, Inc. - Common Stock?
    The market capitalization of Replimune Group, Inc. - Common Stock is 626.74M
    How many shares of Replimune Group, Inc. - Common Stock are outstanding?
    Replimune Group, Inc. - Common Stock has 627M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.